Results 191 to 200 of about 1,361,764 (281)

Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Objective To investigate the clinical characteristics of newly diagnosed multiple myeloma (NDMM) patients with 1q21 gain/amplification (1q21+), construct and validate a progression‐free survival (PFS) prediction model, and explore the clinical implications of model‐based risk stratification.
Yuexuan Rao, Shiyou Li, Aoyang Yu, Wenjie Yu, Zhiyuan Yao, Huanxin Zhang, Zhenyu Li   +6 more
wiley   +1 more source

Association of hemoglobin level with granulocyte engraftment and red blood cell transfusion by transplant type after hematopoietic stem cell transplantation: a retrospective cohort study. [PDF]

Ann Med
Wang J, Wang J, Ying Q, Lv D, Zhang P.
europepmc   +1 more source

Efficacy and Safety of CAR‐T Cell Therapy in Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia With Central Nervous System Involvement

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Central nervous system (CNS) involvement in B‐cell acute lymphoblastic leukemia (B‐ALL) is associated with relapse, treatment refractoriness, and poor prognosis. Although chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (R/R) B‐ALL, its efficacy and safety in CNS leukemia (CNSL) remain ...
Yanghong Yu, Hui Xu, Lei Xue, Xingbing Wang   +3 more
wiley   +1 more source

Multidisciplinary Team Nursing Care During Peri-Transplantation for ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report. [PDF]

Cancer Manag Res
Hong X, Wang G, Cai L, Lin Y, Zhao Y.
europepmc   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 745-752, September 2026.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft, Estelle Marrer‐Berger, Sara Belli, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Michael Bscheider, Wolfgang Jacob, Martin Weisser, Laura Blanco, Nicolas Frances, Eva Rossmann, Guido Steiner, Aintzane Zabaleta Azpiroz, Bruno Paiva, Ludovic Martinet, Tanja Fauti   +16 more
wiley   +1 more source

Temperature Safeguards and Peri-Procedural Strategies for Stem Cell Collection in Cold Agglutinin Disease: A Case Report and Literature Review. [PDF]

J Clin Apher
Bellegarde S, Scott C, Sabol R, Eunson T, Gahvari ZJ, Onyenekwu CP.   +5 more
europepmc   +1 more source

Mass culture of equine synovial fluid‐derived mesenchymal stromal cells using nonwoven polyethylene terephthalate fabrics

Equine Veterinary Journal, Volume 58, Issue 5, Page 1454-1466, September 2026.
Abstract Background Culture protocols need to yield 100 million equine synovial fluid (SF)‐derived mesenchymal stromal cells (SF‐MSCs) in around 3 weeks are needed, before these cells can be evaluated as agents of articular repair in clinical trials. Objectives To investigate mass culture of equine SF‐MSC culture protocols using nonwoven polyethylene ...
Miho Daniel Yoshitomi, Tomohide Kuramoto, Takashi Hatazoe, Kenta Mitsuda, Henry Smith, Kazuhiro Misumi   +5 more
wiley   +1 more source

Autologous immune system reset for kidney allograft acceptance: mechanisms, evidence, and a testable reconstitution-window model. [PDF]

Front Med (Lausanne)
Lyu C, Chen Z, Zhao D.
europepmc   +1 more source

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Minimal residual disease (MRD) is the standard for deep response assessment in multiple myeloma but requires bone marrow sampling. Whether early serum free light chain (sFLC) response provides independent prognostic information in real‐world, predominantly non‐transplant patients remains unclear.
Yubiao Pan, Yue Wang, Yaqin Xiong, Panpan Li, Chenqi Yu, Peng Liu   +5 more
wiley   +1 more source

Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans. [PDF]

Sci Transl Med
Barve A, Dabas P, Cornwell A, Sriram P, Kopyov A, Zhai M, Kooienga E, Kelley Z, Johnson J, Myers JA, Obeng EA, Kang G, Olufadi Y, Cain T, Talbot L, Spence D, Cortes M, Miller SA, Loeffler D, Sharma A, McKinney-Freeman S.   +20 more
europepmc   +1 more source